Abstract
Metabolic syndrome is a risk factor for the development of cardiovascular disease. Few prospective studies, however, have examined metabolic syndrome as a risk factor for chronic kidney disease (CKD) in an Asian population. We studied the occurrence of CKD in 6,371 subjects without CKD or diabetes mellitus at baseline 1997 through 2002 in Okinawa, Japan. CKD was defined as dipstick-positive proteinuria (≥1+) or a low estimated glomerular filtration rate (<60 mL/min/1.73 m2). Metabolic syndrome was defined according to the modified criteria of the Adult Treatment Panel III in which body mass index (≥25 kg/m2) was substituted for the waist circumference measurement. Logistic analysis was used to analyze the effect of metabolic syndrome on the development of CKD. During the 5-year follow-up, 369 (5.7%) participants developed CKD. After adjusting for age, sex, current cigarette smoking and alcohol drinking habits at baseline, the relative risk of developing CKD was 1.86 (95% confidence interval: 1.43–2.41, p<0.0001) in subjects with metabolic syndrome. Compared with those without metabolic syndrome risk components, the adjusted relative risk (95% confidence interval) was 1.49 (1.10–2.01), 1.89 (1.38–2.59), and 2.65 (1.19–3.68) in those with 1, 2, or ≥3 metabolic syndrome risk components, respectively. Metabolic syndrome is a significant risk factor for the development of CKD in the Japanese population. Detection and treatment of metabolic syndrome should be stressed as a strategy to prevent CKD.
Similar content being viewed by others
Article PDF
References
Lakka HM, Laalsonen DE, Lakka TA, et al: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA 2002; 288: 2709–2716.
Takeuchi H, Saitoh S, Takagi S, et al: Metabolic syndrome and cardiac disease in Japanese men: applicability of the concept of metabolic syndrome defined by the National Cholesterol Education Program–Adult Treatment Panel III to Japanese men—the Tanno and Sobetsu Study. Hypertens Res 2005; 28: 203–208.
Japanese Society for Dialysis Therapy : An overview of regular dialysis treatment in Japan: as of December 21, 2005. http://www.jsdt.or.jp
Iseki K, Tozawa M, Iseki C, Takishita S, Ogawa Y : Demographic trends in the Okinawa Dialysis Study (OKIDS) registry (1971–2000). Kidney Int 2002; 61: 668–675.
Usami T, Koyama K, Takeuchi O, Morozumi K, Kimura G : Regional variations in the incidence of end-stage renal failure in Japan. JAMA 2000; 284: 2622–2624.
Tanaka H, Shimabukuro T, Shimabukuro M : High prevalence of metabolic syndrome among men in Okinawa. J Atheroscler Thromb 2005; 12: 284–288.
Iseki K, Kohagura K, Sakima A, et al: Changes in the demographic and prevalence of chronic kidney disease in Okinawa, Japan (1993 to 2002). Hypertens Res 2007; 30: 55–62.
Chen J, Muntner P, Hamm LL, et al: The metabolic syndrome and chronic kidney disease in U.S. adults. Ann Intern Med 2004; 140: 167–174.
Tanaka H, Shiohira Y, Uezu Y, Higa A, Iseki K : Metabolic syndrome and chronic kidney disease in Okinawa, Japan. Kidney Int 2006; 69: 369–374.
Kurella M, Lo JC, Chertow GM : Metabolic syndrome and the risk for chronic kidney disease among nondiabetic adults. J Am Soc Nephrol 2005; 16: 2134–2140.
Mandavilli A, Cyranoski D : Asia's big problem. Nat Med 2004; 10: 325–327.
Ninomiya T, Kiyohara Y, Kubo M, et al: Metabolic syndrome and CKD in a general Japanese population: the Hisayama Study. Am J Kidney Dis 2006; 48: 383–391.
Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S : Influence of smoking and obesity on the development of proteinuria. Kidney Int 2002; 62: 956–962.
Tozawa M, Iseki K, Iseki C, Oshiro S, Ikemiya Y, Takishita S : Triglyceride, but not total cholesterol or low-density lipoprotein cholesterol levels, predict development of proteinuria. Kidney Int 2002; 62: 1743–1749.
Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults : Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–2497.
Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D, Modification of Diet in Renal Disease Study Group: A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med 1999; 130: 461–470.
Kopple JD : National kidney foundation K/DOQI clinical practice guidelines for nutrition in chronic renal failure. Am J Kidney Dis 2001; 37 ( 1 Suppl 2): S66–S70.
Petrie A, Sabin C : Medical Statistics at a Glance. Oxford, Blackwell Science, Ltd, 2000, pp 64–66.
Levey AS, Eckardt KU, Tsukamoto Y, et al: Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005; 67: 2089–2100.
Kramer H, Luke A, Bidani A, Cao G, Cooper R, McGee D : Obesity and prevalent and incident CKD: the Hypertension Detection and Follow-Up Program. Am J Kidney Dis 2005; 46: 587–594.
Ejerblad E, Fored CM, Lindblad P, Fryzek J, McLaughlin JK, Nyren O : Obesity and risk for chronic renal failure. J Am Soc Nephrol 2006; 17: 1695–1702.
Bonnet F, Deprele C, Sassolas A, et al: Excessive body weight as a new independent risk factor for clinical and pathological progression in primary IgA nephritis. Am J Kidney Dis 2001; 37: 720–727.
Gelber RP, Kurth T, Kausz AT, et al: Association between body mass index and CKD in apparently healthy men. Am J Kidney Dis 2005; 46: 871–880.
Hsu CY, McCulloch CE, Iribarren C, Darbinian J, Go AS : Body mass index and risk for end-stage renal disease. Ann Intern Med 2006; 144: 21–28.
Ribstein J, du Cailar G, Mimran A : Combined renal effects of overweight and hypertension. Hypertension 1995; 26: 610–615.
Kasiske BL, Crosson JT : Renal disease in patients with massive obesity. Arch Intern Med 1986; 146: 1105–1109.
Henegar JR, Bigler SA, Henegar LK, Tyagi SC, Hall JE : Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol 2001; 12: 1211–1217.
Gu JW, Wang J, Stockton A, Lokitz B, Henegar L, Hall JE : Cytokine gene expression profiles in kidney medulla and cortex of obese hypertensive dogs. Kidney Int 2004; 66: 713–721.
Muntner P, Coresh J, Smith JC, Eckfeldt J, Klag MJ : Plasma lipids and risk of developing renal dysfunction: the atherosclerosis risk in communities study. Kidney Int 2000: 58: 293–301.
Keane WF, O'Donnell MP, Kasiske BL, Kim Y : Oxidative modification of low-density lipoproteins by mesangial cells. J Am Soc Nephrol 1993; 4: 187–194.
Nishida Y, Yorioka N, Oda H, Yamakido M : Effect of lipoproteins on cultured human mesangial cells. Am J Kidney Dis 1997; 29: 919–930.
Berfield AK, Andress DL, Abrass CK : IGF-1−induced lipid accumulation impairs mesangial cell migration and contractile function. Kidney Int 2002; 62: 1229–1237.
Wang Z, Jiang T, Li J, et al: Regulation of renal lipid metabolism, lipid accumulation, and glomerulosclerosis in FVBdb/db mice with type 2 diabetes. Diabetes 2005; 54: 2328–2335.
Klag MJ, Whelton PK, Randall BL, et al: Blood pressure and end-stage renal disease in men. N Engl J Med 1996; 334: 13–18.
Tozawa M, Iseki K, Iseki C, Kinjo K, Ikemiya Y, Takishita S : Blood pressure predicts risk of developing end-stage renal disease in men and women. Hypertension 2003; 41: 1341–1345.
Hsu CY, McCulloch CE, Darbinian J, Go AS, Iribarren C : Elevated blood pressure and risk of end-stage renal disease in subjects without baseline kidney disease. Arch Intern Med 2005; 165: 923–928.
Segura J, Campo C, Gil P, et al: Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. J Am Soc Nephrol 2004; 15: 1616–1622.
Nakai S, Wada A, Kitaoka T, et al: An overview of dialysis treatment in Japan (as of Dec. 31, 2004). J Jpn Soc Dial Ther 2006; 39: 1–22.
Kuriyama S : Impact of overweight and obesity on medical care costs, all-cause mortality, and the risk of cancer in Japan. J Epidemiol 2006; 16: 139–144.
Chen YM, Ho SC, Lam SS, Chan SS : Validity of body mass index and waist circumference in the classification of obesity as compared to percent body fat in Chinese middle-aged women. Int J Obes (Lond) 2006; 30: 918–925.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tozawa, M., Iseki, C., Tokashiki, K. et al. Metabolic Syndrome and Risk of Developing Chronic Kidney Disease in Japanese Adults. Hypertens Res 30, 937–943 (2007). https://doi.org/10.1291/hypres.30.937
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.30.937
Keywords
This article is cited by
-
Metabolic syndrome as a risk factor for the development of kidney dysfunction: a meta-analysis of observational cohort studies
Journal of Diabetes & Metabolic Disorders (2023)
-
Association of metabolic syndrome traits with urinary biomarkers in Japanese adults
Diabetology & Metabolic Syndrome (2022)
-
Metabolic syndrome is a predictor of decreased renal function among community-dwelling middle-aged and elderly Japanese
International Urology and Nephrology (2019)
-
Risk of chronic kidney disease in young adults with impaired glucose tolerance/impaired fasting glucose: a retrospective cohort study using electronic primary care records
BMC Nephrology (2018)
-
Metabolic syndrome status over 2 years predicts incident chronic kidney disease in mid-life adults: a 10-year prospective cohort study
Scientific Reports (2018)